Literature DB >> 25920434

Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?

David J Worhunsky1, Mihir Gupta, Sepideh Gholami, Thuy B Tran, Kristen N Ganjoo, Matt van de Rijn, Brendan C Visser, Jeffrey A Norton, George A Poultsides.   

Abstract

BACKGROUND: Leiomyosarcoma (LMS) can originate from the retroperitoneum, uterus, extremity, and trunk. It is unclear whether tumors of different origin represent discrete entities. We compared clinicopathologic features and outcomes following surgical resection of LMS stratified by site of origin.
METHODS: Patients with LMS undergoing resection at a single institution were retrospectively reviewed. Clinicopathologic variables were compared across sites. Survival was calculated using the Kaplan-Meier method and compared using log-rank and Cox regression analyses.
RESULTS: From 1983 to 2011, 138 patients underwent surgical resection for LMS. Retroperitoneal and uterine LMS were larger, higher grade, and more commonly associated with synchronous metastases. However, disease-specific survival, recurrence-free survival, and recurrence patterns were not significantly different across the four sites. Synchronous metastases (HR 3.20, P < 0.001), but not site of origin, size, grade, or margin status, were independently associated with worse DSS. A significant number of recurrences and disease-related deaths were noted beyond 5 years.
CONCLUSIONS: Although larger and higher grade, retroperitoneal and uterine LMS share similar survival and recurrence patterns with their trunk and extremity counterparts. LMS of various anatomic sites may not represent distinct disease processes based on clinical outcomes. The presence of metastatic disease remains the most important prognostic factor for LMS.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  leiomyosarcoma; outcome assessment; sarcoma

Mesh:

Year:  2015        PMID: 25920434     DOI: 10.1002/jso.23904

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.

Authors:  Ching-Yao Yang; Jau-Yu Liau; Wei-Ju Huang; Yu-Ting Chang; Ming-Chu Chang; Jen-Chieh Lee; Jia-Huei Tsai; Yi-Ning Su; Chia-Cheng Hung; Yung-Ming Jeng
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 2.  Emerging Opportunities for Target Discovery in Rare Cancers.

Authors:  Tanaz Sharifnia; Andrew L Hong; Corrie A Painter; Jesse S Boehm
Journal:  Cell Chem Biol       Date:  2017-09-21       Impact factor: 8.116

Review 3.  Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma.

Authors:  Heather Miller; Chiemeka Ike; Jennifer Parma; Ramya P Masand; Claire M Mach; Matthew L Anderson
Journal:  Sarcoma       Date:  2016-09-19

Review 4.  Leiomyosarcoma in the extremities and trunk wall: systematic review and meta-analysis of the oncological outcomes.

Authors:  Sudhir Kannan; Han Hong Chong; Bryan Chew; Jay Dee Ferguson; Euan Galloway; Thomas McCulloch; Kenneth S Rankin; Robert U Ashford
Journal:  World J Surg Oncol       Date:  2022-04-18       Impact factor: 3.253

5.  Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma.

Authors:  Nesrin M Hasan; Anup Sharma; Nensi M Ruzgar; Hari Deshpande; Kelly Olino; Sajid Khan; Nita Ahuja
Journal:  Oncotarget       Date:  2021-08-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.